Articles

Patient-reported outcomes from nearly 2000 women with gynecologic cancers revealed that black women have more suffering, less support, and worse health than white women. Read More ›

Progression-free survival was significantly increased with olaparib plus bevacizumab as maintenance therapy overall and across all important subgroups. Read More ›

Initial findings from a large-scale, patient-reported outcomes program reveal that patients with gynecologic malignancy do not report worse quality of life after surgery. Read More ›

New research shows that treatment with niraparib does not negatively impact quality of life in patients with ovarian cancer. Read More ›

In an exploratory analysis of a phase 3 study, niraparib improved progression-free survival in patients with advanced ovarian cancer across all important subgroups. Read More ›

Preliminary data on time to first subsequent therapy and second progression-free survival support clinical benefit of niraparib over placebo. Read More ›

Leaders in oncology pharmacy tackle some of the biggest issues in the field today in a pre-summit professional development session. Read More ›

Stakeholders address the challenge of integrating high-cost therapies into cancer care delivery. Read More ›

Payers identify strategies for promoting value-based, high-quality cancer care. Read More ›

A pair of distinguished keynote speakers gave attendees a rare behind-the-scenes look at healthcare policy decisions at the highest levels. Read More ›